Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes

Bibliography

• Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;24:2560-72
   Google Scholar
• Holmann RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;15:1577-89
   Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. JAMA 2007;298:194-206
   PubMed Web of Science ®Google Scholar
• Moore KB, Saudek CD. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. Am J Ther 2008;15:484-91
   PubMed Web of Science ®Google Scholar
• Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004;36:2-8
   Google Scholar
• Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-4
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen J, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
   PubMed Web of Science ®Google Scholar
• Lerche S, Soendergaard L, Rungby J, et al. No increased risk of hypoglycaemic episodes during 48 hours of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. Clin Endocrinol (Oxf) 2008 [Epub ahead of print]
   PubMedGoogle Scholar
• Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-43
   PubMed Web of Science ®Google Scholar
• Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70
   PubMed Web of Science ®Google Scholar
• Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94
   PubMed Web of Science ®Google Scholar
• Burkey BF, Hoffman PK, Hassiepen U, et al. Adverse effects of dipeptidyl peptidases 8 & 9 inhibition in rodents revisited. Diabetes Obes Metab 2008;10:1057-61
   PubMed Web of Science ®Google Scholar
• Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998;47:764-9
   PubMed Web of Science ®Google Scholar
• Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;5:869-75
   Google Scholar
• Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008;93:3703-16
   PubMed Web of Science ®Google Scholar
• Thomas L, Eckhardt M, Langkopf E, et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008;325:175-82
   PubMed Web of Science ®Google Scholar
• Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007;50:6450-3
   PubMed Web of Science ®Google Scholar
• Dittberner S, Duval V, Staab A, et al. Determination of the absolute bioavailability of BI 1356 a substance with non linear pharmacokinetics using a population pharmacokinetic modeling approach [abstract 1110]. 16th Meet Popul Approach Group Eur (June 13, Copenhagen) 2008
   Google Scholar
• Hüttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171-8
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U, Padula SJ, Dugi KA, et al. The novel DPP-4 inhibitor BI 1356 (Proposed radename ONDERO) and metformin can be safely co-administered without dose adjustment. Diabetes 2008;57:A164
   Google Scholar
• Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-yl methyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009;328:556-63
   PubMed Web of Science ®Google Scholar
• Thomas L, Himmelsbach F, Eckhardt M, et al. BI 1356, a novel and selective xanthine based DPP-IV inhibitor, exhibits a superior profile when compared to sitagliptin and vildagliptin. Diabetologia 2007;50:S363
   Google Scholar
• Sesoko S, Nakajima M, Hayashi N, et al. Safety, Tolerability and pharmacodynamics of single and multiple oral doses of the dipeptidyl peptidase 4 inhibitor BI 1356 in healthy Japanese volunteers. Diabetes 2008;57:A159
   Google Scholar
• Wang Y. BI-1356 – dipeptidyl-peptidase IV inhibitor, antidiabetic agent. Drugs Future 2008;33:1171-8
   Google Scholar
• Forst T, Uhlig-Laske B, Ring A, et al. The novel, potent, and selective DPP-IV inhibitor B1 1356 significantly lowers HbA1c after only 4 weeks of treatment in patients with type 2 diabetes. Diabetes 2007;56:A157-8
   Google Scholar
• Heise T, Tiessen R, Hüttner, et al. Treatment with BI 1356, a novel and potent DPP-IV inhibitor, significantly reduces glucose excursions after an oGTT in patients with type 2 diabetes. Diabetes 2007;56:A156
   Google Scholar